B
Bullisch
Bullisch · 25%REGN
$785.14
Szenariopreis
$807.480
+26.243 (+3.25%)Zum Schluss
Loading chart…
- Hoch
- 807.860
- Eröffnung
- 793.850
- Volumengewichteter Durchschnittskurs
- 801.68
- Volumen
- 623.40K
- Marktkap.
- 115.79B
- Tief
- 789.690
- Umsatz
- 499.77M
- EV/EBITDA, TTM
- 11.98
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
KI-Analyse of Regeneron Pharmaceuticals Inc (REGN)
KaufenRegeneron Pharmaceuticals Inc is a good buy right now, trading at $790.74 with a strong forward P/E of 14.51, indicating potential for earnings growth. The recent positive Phase 3 trial results for Pasatru highlight significant efficacy, which could drive future revenue. Additionally, hedge funds have increased their buying activity by 167% over the last quarter, suggesting strong institutional confidence. However, the RSI is at 69.33, indicating that the stock may be nearing overbought territory, which is a risk to consider.
Analystenbewertungen (26)
+0.13% Aufwärtspotenzial
Kaufen
13 Kaufen
12 Halten
1 Verkaufen
Aktuell: 807.48
Tief
637.00
Durchschnitt
808.50
Hoch
—
BofA
Kaufen
$908
2026-10-12
BofA
2026-10-12
Kursziel
$908
Kaufen
RBC Capital
Sector Perform
$810
2026-10-08
RBC Capital
2026-10-08
Kursziel
$810
Sector Perform
Truist
Kaufen
$780
2026-10-07
Truist
2026-10-07
Kursziel
$780
Kaufen
Morgan Stanley
Equal Weight
$779
2026-10-07
Morgan Stanley
2026-10-07
Kursziel
$779
Equal Weight
JPMorgan
Übergewichten
$950
2026-10-06
JPMorgan
2026-10-06
Kursziel
$950
Übergewichten
Bewertungskennzahlen
Das aktuelle erwartete KGV von Regeneron Pharmaceuticals Inc (REGN) beträgt 14.51, verglichen mit dem 5-Jahres-Durchschnitt von 16.99.
Alphio-AI-Kursszenarien für REGN
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die REGN halten
Event-Zeitleiste
News
5.010-19FoolWeight Loss Drug Market Rapid Growth
8.510-19stocktwitsModerna and Merck Present Phase 3 Melanoma Findings for Personalized Cancer Treatment
9.510-17FoolRegeneron Faces Sales Challenges Despite Dupixent Growth
8.510-16NewsfilterPositive Opinion for Libtayo Dosing Adjustment
6.010-15CNBCLatest Wall Street Rating Updates
REGN FAQ – beantwortet von Alphio AI
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Regeneron Pharmaceuticals Inc is a good buy right now, trading at $790.74 with a strong forward P/E of 14.51, indicating potential for earnings growth. The recent positive Phase 3 trial results for Pasatru highlight significant efficacy, which could drive future revenue. Additionally, hedge funds have increased their buying activity by 167% over the last quarter, suggesting strong institutional confidence. However, the RSI is at 69.33, indicating that the stock may be nearing overbought territory, which is a risk to consider.
26 analysts cover REGN: 13 rate it Buy, 12 Hold and 1 Sell. The average price target is 808.50.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.